Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optical, Structural, and Dielectric Properties of Composites Based on Thermoplastic Polymers of the Polyolefin and Polyurethane Type and BaTiO<sub>3</sub> Nanoparticles.

Materials (Basel, Switzerland)·2021
Same author

Amelioration of non-motor dysfunctions after transplantation of human dopamine neurons in a model of Parkinson's disease.

Experimental neurology·2016
Same author

A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.

Cancer chemotherapy and pharmacology·2011
Same author

Mobile versus fixed site lithotripsy: Assessor's Comment.

Annals of the Royal College of Surgeons of England·2009
Same author

Uptake of invasive testing following a positive triple test for Down's syndrome. Are midwives different counsellors compared with obstetricians?

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology·2007
Same author

Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer: a California Cancer Consortium Trial.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2007

Related Experiment Video

Updated: Jun 8, 2026

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting
07:54

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting

Published on: March 25, 2019

Targeted agents in ovarian cancer.

T S Kristedja1, R J Morgan, M Cristea

  • 1Department of Medical Oncology &amp; Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.

Women'S Health (London, England)
|October 5, 2010
PubMed
Summary

Targeted therapies show promise for ovarian cancer, offering new hope against disease recurrence. Ongoing trials explore novel agents like poly-ADP-ribose polymerase inhibitors for improved patient outcomes.

Area of Science:

  • Gynecologic Oncology
  • Medical Oncology
  • Pharmacology

Background:

  • Ovarian cancer frequently recurs despite treatment advances.
  • Targeted therapies have transformed other cancer care but lack FDA approval for ovarian cancer.
  • Existing Phase II data shows promise for targeted agents in ovarian cancer management.

Purpose of the Study:

  • To review the current landscape of targeted therapies for ovarian cancer.
  • To identify promising agents and future directions in ovarian cancer treatment.

Main Methods:

  • Review of existing clinical trial data (Phase II and III).
  • Analysis of targeted therapy classes including monoclonal antibodies, tyrosine kinase inhibitors, antiangiogenic agents, and poly-ADP-ribose polymerase inhibitors.

More Related Videos

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Related Experiment Videos

Last Updated: Jun 8, 2026

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting
07:54

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting

Published on: March 25, 2019

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

  • Discussion of ongoing research and development.

    • Main Results:

    • No targeted therapies are FDA-approved for ovarian cancer, but Phase II trials show potential.
    • Antiangiogenic agents are in Phase III trials for adjuvant and recurrent settings.
    • Poly-ADP-ribose polymerase inhibitors demonstrate promise, especially in BRCA1/2-mutated cancers, with ongoing trials.

    Conclusions:

    • Targeted therapies represent a significant area of development for ovarian cancer.
    • Further research and clinical trials are crucial to realize the potential of these agents.
    • Future directions include combination therapies and agents targeting specific mutations.